While HER2 + breast cancer trials, such as BCIRG-006, demonstrated comparable outcomes between anthracycline-free (PCb) and anthracycline-containing (EC-P) regimens under anti-HER2 therapy [9], TNBC lacks consensus. This evidence concerns the gene ERBB2 and breast cancer.